Pharma · Private company
Novartis Pharmaceuticals
Track this companyFree. Adds Novartis Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs44From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline44
- AnsastrozolePhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CorticosteroidsPhase 3 · Primary Immune Thrombocytopenia (ITP)ClinicalTrials.gov · fetched Nov 12, 2026
- CrizanlizumabPhase 3 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- DupilumabPhase 3 · Chronic Spontaneous Urticaria (CSU)ClinicalTrials.gov · fetched Nov 12, 2026
- EltrombopagPhase 3 · Primary Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
- ExemestanePhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GoserelinPhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- IanalumabPhase 3 · Primary Immune Thrombocytopenia (ITP)ClinicalTrials.gov · fetched Nov 12, 2026
- IanalumabPhase 3 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- IanalumabPhase 3 · Primary Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
- IanalumabPhase 3 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
- LetrozolePhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LeuprolidePhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PelabresibPhase 3 · Primary Myelofibrosis (PMF)ClinicalTrials.gov · fetched Nov 12, 2026
- RemibrutinibPhase 3 · Chronic Spontaneous Urticaria (CSU)ClinicalTrials.gov · fetched Nov 12, 2026
- RibociclibPhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RuxolitinibPhase 3 · Primary Myelofibrosis (PMF)ClinicalTrials.gov · fetched Nov 12, 2026
- 68Ga-PSMA-11Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)ClinicalTrials.gov · fetched Nov 12, 2026
- AAA617Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)ClinicalTrials.gov · fetched Nov 12, 2026
- AbirateronePhase 2 · Metastatic Hormone-sensitive Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- AlpelisibPhase 2 · PIK3CA-related Overgrowth Spectrum (PROS)ClinicalTrials.gov · fetched Nov 12, 2026
- Asciminib Adult formulation groupPhase 2 · Myeloid Leukemia, Philadelphia PositiveClinicalTrials.gov · fetched Nov 12, 2026
- Asciminib Pediatric formulation groupPhase 2 · Myeloid Leukemia, Philadelphia PositiveClinicalTrials.gov · fetched Nov 12, 2026
- Asciminib single agentPhase 2 · Chronic Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BenznidazolePhase 2 · Chagas DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Cryptosporidium parvum oocysts (ABO809)Phase 2 · CryptosporidiosisClinicalTrials.gov · fetched Nov 12, 2026
- EDI048Phase 2 · CryptosporidiosisClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 2 · Metastatic Hormone-sensitive Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- IanalumabPhase 2 · Diffuse Cutaneous Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- JSB462Phase 2 · Metastatic Hormone-sensitive Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- LOU064Phase 2 · Papulopustular RosaceaClinicalTrials.gov · fetched Nov 12, 2026
- LXE408Phase 2 · Chagas DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LOU064Phase 1 · Hidradenitis SuppurativaClinicalTrials.gov · fetched Nov 12, 2026
- OJR520Phase 1 · Chronic Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SecukinumabPhase 1 · Juvenile Psoriatic ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- Asciminib single agent pediatric formulationChronic Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BosutinibChronic Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- dabrafenibMelanomaClinicalTrials.gov · fetched Nov 12, 2026
- DasatinibChronic Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ImatinibChronic Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- KesimptaMultiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- NilotinibChronic Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Secukinumab s.c. injectionAutoimmunity, InflammationClinicalTrials.gov · fetched Nov 12, 2026
- trametinibMelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSPHASE1 · RECRUITING · started Oct 29, 2026ClinicalTrials.gov NCT07855276 · fetched Nov 12, 2026
- A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)PHASE2 · RECRUITING · started Jul 30, 2026ClinicalTrials.gov NCT07681271 · fetched Nov 12, 2026
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)PHASE3 · RECRUITING · started May 27, 2026ClinicalTrials.gov NCT07357727 · fetched Nov 12, 2026
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPPHASE2 · RECRUITING · started Apr 28, 2026ClinicalTrials.gov NCT07354074 · fetched Nov 12, 2026
- Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy AdultsPHASE2 · RECRUITING · started Dec 8, 2025ClinicalTrials.gov NCT07249463 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney DiseasePHASE1 · RECRUITING · started Nov 20, 2025ClinicalTrials.gov NCT07235059 · fetched Nov 12, 2026
- EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)PHASE2 · RECRUITING · started Oct 9, 2025ClinicalTrials.gov NCT06997588 · fetched Nov 12, 2026
- Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).PHASE1 · RECRUITING · started Sep 24, 2025ClinicalTrials.gov NCT06751238 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 11, 2025ClinicalTrials.gov NCT06868212 · fetched Nov 12, 2026
- An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 7, 2025ClinicalTrials.gov NCT06991556 · fetched Nov 12, 2026
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)PHASE3 · RECRUITING · started May 19, 2025ClinicalTrials.gov NCT06711887 · fetched Nov 12, 2026
- A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.PHASE2 · RECRUITING · started Apr 28, 2025ClinicalTrials.gov NCT06632600 · fetched Nov 12, 2026
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)PHASE3 · RECRUITING · started Oct 24, 2024ClinicalTrials.gov NCT06439082 · fetched Nov 12, 2026
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 9, 2024ClinicalTrials.gov NCT06470048 · fetched Nov 12, 2026
- Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaPHASE1_PHASE2 · RECRUITING · started Aug 5, 2024ClinicalTrials.gov NCT06308588 · fetched Nov 12, 2026
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).PHASE3 · RECRUITING · started May 21, 2024ClinicalTrials.gov NCT06133972 · fetched Nov 12, 2026
- Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 4, 2024ClinicalTrials.gov NCT06004661 · fetched Nov 12, 2026
- Phase IIIb Study of Ribociclib + ET in Early Breast CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 28, 2024ClinicalTrials.gov NCT05827081 · fetched Nov 12, 2026
- Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)PHASE3 · ACTIVE_NOT_RECRUITING · started Feb 3, 2023ClinicalTrials.gov NCT05653349 · fetched Nov 12, 2026
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 2, 2023ClinicalTrials.gov NCT05653219 · fetched Nov 12, 2026
- Kesimpta (Ofatumumab) Pregnancy RegistryRECRUITING · started Jan 5, 2023ClinicalTrials.gov NCT05634967 · fetched Nov 12, 2026
- Asciminib Roll-over StudyPHASE4 · RECRUITING · started Aug 30, 2022ClinicalTrials.gov NCT04877522 · fetched Nov 12, 2026
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 27, 2021ClinicalTrials.gov NCT04925479 · fetched Nov 12, 2026
- Secukinumab Open Label Roll-over Extension ProtocolPHASE4 · RECRUITING · started Dec 22, 2020ClinicalTrials.gov NCT04638647 · fetched Nov 12, 2026
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · RECRUITING · started Jan 26, 2018ClinicalTrials.gov NCT03340506 · fetched Nov 12, 2026